TP53RK binding protein pseudogene 2Genealiases: []
Q-omics provides the consensus-scored TPRKBP2 profile across patient tissues and cancer cell-line models. TPRKBP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TPRKBP2 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TPRKBP2 RNA expression shows 10,523 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight THCA, HNSC, and LAML as cancer lineages where TPRKBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPRKBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPRKBP2 survival associations across molecular data types. TPRKBP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPRKBP2 RNA expression–survival associations across cancer types. High TPRKBP2 expression shows unfavorable associations in THCA and KIRP, but favorable associations in KIRC, READ, KICH and LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify THCA as the clearest survival context for TPRKBP2 RNA expression.
This table summarizes TPRKBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TPRKBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPRKBP2 shows lower tumor expression in THCA and higher tumor expression in HNSC, BRCA, CHOL, COAD and PAAD. The HNSC box plot shows higher TPRKBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.064, t-test p = .001).
This table shows molecular features associated with TPRKBP2 in patient tissues and cancer cell lines. In patient samples, TPRKBP2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
